Jump to content

Draft:CT-996

From Wikipedia, the free encyclopedia

CT-996 is an once daily oral small molecule GLP-1 agonist developed to treat obesity and type 2 diabetes.[1] It is designed with minimal-to-no beta-arrestin recruitment.[2] In a double-blind, randomized, placebo-controlled Phase I clinical trial participants averaged 6.1 percent placebo adjusted weight loss within four weeks.[3][4][5][6] The drug is being developed by Roche/Genentech after Roche's takeover of Carmot Therapeutics in January 2024.[7][8]

References

[edit]
  1. ^ owenhaskins (2023-10-12). "Carmot's CT-996 GLP-1 candidate supports once-daily oral dosing for obesity and type 2 diabetes". Bariatric News. Retrieved 2024-07-28.
  2. ^ "Clinical Trials | Carmot Therapeutics | Drug Discovery and Development". Carmot Therapeutics. Retrieved 2024-07-26.
  3. ^ "Roche - Press release, July 17, 2024". www.roche.com. Retrieved 2024-07-26.
  4. ^ "CT-996 Demonstrates Significant Weight Loss in Patients with Obesity and Type 2 Diabetes". PharmExec. 2024-07-18. Retrieved 2024-07-26.
  5. ^ "ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2024-07-28.
  6. ^ "Handelsblatt". www.handelsblatt.com (in German). Retrieved 2024-07-28.
  7. ^ Brody, Micaela (2024-01-29). "Carmot Therapeutics Announces Completion of Acquisition by Roche | Carmot Therapeutics | Drug Discovery and Development". Carmot Therapeutics. Retrieved 2024-07-26.
  8. ^ Burger, Ludwig (December 4, 2023). "Roche joins race for obesity drugs with $2.7 billion Carmot deal". Reuters. Retrieved July 28, 2024.